IOMX 0675
Alternative Names: IOMX-0675Latest Information Update: 17 Oct 2024
At a glance
- Originator iOmx Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action LILRB2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Sep 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 8th Annual International Cancer, Immunotherapy Conference (CICON-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research
- 03 Apr 2024 Preclinical trials in Solid tumours in Germany (Parenteral)